Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI302 longer interval dosing in nAMD
NCT05403749Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efdamrofusp alfa in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Innovent Biologics. Primary endpoint: Change of Best Corrected Visual Acuity from baseline at 40 weeks. Started Jun 2022; status: completed.
02
Drugs
efdamrofusp alfa
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05403749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403749.